SuperworthAngiodynamics profit margin ANGO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −10.1%
- Operating margin, 12 months
- −11.2%
- Net margin on a year earlier
- +0.6 pts
- Peer median
- 6.5%
Over the twelve months to Aug 31, 2026, Angiodynamics kept −10.1% of its revenue as net profit, with an operating margin of −11.2% and a gross margin of 55.7%.
Five years earlier its net margin was −11.5%.
The median for 10 medical instruments and supplies stocks of a similar size is 6.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | −11.5% | −12.5% | 54.6% |
| FY2025 | −11.6% | −13.7% | 53.9% |
| FY2024 | −60.7% | −63.3% | 50.9% |
| FY2023 | −15.5% | −15.1% | 51.4% |
| FY2022 | −8.4% | −9.0% | 52.4% |
| FY2021 | −10.8% | −12.1% | 53.9% |
| FY2020 | −63.1% | −63.3% | 56.9% |
| FY2019 | 22.7% | −3.5% | 57.6% |
| FY2018 | 6.2% | 4.0% | 55.0% |
| FY2017 | 1.4% | 3.7% | 50.4% |
| FY2016 | −12.3% | 0.3% | 49.3% |
| FY2015 | −1.0% | −1.0% | 49.3% |
| FY2014 | 0.8% | 3.7% | 50.7% |
| FY2013 | −0.4% | 2.1% | 49.3% |
| FY2012 | −2.3% | −1.3% | 56.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q1 FY27 | −10.1% | +0.6 pts | −11.2% | |
| Q4 FY26 | −11.5% | +0.1 pts | −12.5% | |
| Q3 FY26 | −10.0% | +4.6 pts | −11.3% | |
| Q2 FY26 | −9.0% | +69.4 pts | −10.6% | |
| Q1 FY26 | −10.7% | +72.3 pts | −12.5% | |
| Q4 FY25 | −11.6% | +49.0 pts | −13.7% | |
| Q3 FY25 | −14.6% | +44.8 pts | −17.2% | |
| Q2 FY25 | −78.4% | −74.2 pts | −83.3% | |
| Q1 FY25 | −83.0% | −84.9 pts | −82.2% | |
| Q4 FY24 | −60.7% | −45.2 pts | −63.3% | |
| Q3 FY24 | −59.4% | −48.2 pts | −61.4% | |
| Q2 FY24 | −4.3% | +5.7 pts | −2.4% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Angiodynamics' size, closest first, today.
| Company | Profit margin |
|---|---|
| ANGOAngiodynamics | −10.1% |
| TCMDTactile Systems Technology | 7.1% |
| MDXGMimedx | 1.8% |
| MOVMovado | 6.0% |
| EMBCEmbecta | 8.6% |
| INFUInfuSystem | 6.0% |
| IRMDIradimed | 26.7% |
| STAAStaar Surgical | 1.1% |
| UTMDUtah Medical Products | 29.0% |
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| Peer median | 6.5% |
Where Angiodynamics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Angiodynamics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.